SYMBICORT: Uses, Forms and Safety Reference

SYMBICORT pairs budesonide with formoterol in a US metered-dose aerosol inhaler. This reference follows that product's maintenance label and keeps other devices and country-specific treatment approaches outside its scope.

The approved uses and formulations described here follow US prescribing information. They may differ in other countries.

Medicine detail Details
Active ingredient(s) budesonide / formoterol fumarate dihydrate
Medicine class Inhaled corticosteroid / long-acting beta2 agonist (ICS/LABA)
Forms and strengths US metered-dose inhalation aerosol: 80/4.5 or 160/4.5 mcg per actuation; Turbuhaler and Aerosphere excluded

The inhaler presentation defines this reference

The cited US aerosol supplies 80/4.5 or 160/4.5 mcg of budesonide/formoterol per actuation. It is distinct from Turbuhaler and Aerosphere presentations. A familiar brand name across countries does not establish identical device technique, component amounts or approved instructions.

Source: [1]

US asthma and COPD roles

The cited label includes asthma in patients aged 6 and older and maintenance treatment of airflow obstruction and reduction of COPD exacerbations. Pediatric asthma has age-specific strength directions, while the COPD regimen uses the 160/4.5 presentation. The label states that this product is not indicated for relief of acute bronchospasm.

Source: [1]

Technique, priming and mouth care

The aerosol needs correct shaking, priming and coordinated inhalation as described in its instructions. A pharmacist or respiratory clinician should check technique with the actual device. Rinse the mouth with water and spit after treatment to help reduce thrush risk. Do not infer a new rescue schedule from formoterol's presence.

Source: [1]

Adverse effects and deteriorating breathing

Oral candidiasis and pneumonia in COPD are among the labeled concerns. Corticosteroid exposure can affect adrenal function, bone, growth and eyes, while beta-agonist effects can include tremor or palpitations. Sudden worsening immediately after an inhalation needs prompt assessment. Increasing breathlessness calls for the established action plan and clinical review.

Source: [1]

Check all inhalers for duplicated ingredients

Do not combine SYMBICORT with another LABA-containing product without a prescribing review; the label warns of overdose risk. Strong CYP3A4 inhibitors and other interacting medicines also need checking. Guideline-directed use in other settings should be discussed with the clinician and must not be presented as an expansion of this US label.

For related product context, see the ADVAIR DISKUS and SYMBICORT comparison; treatment changes still require a prescribing review.

Source: [1]

Questions and answers

Is SYMBICORT Turbuhaler included in this page?

No. This reference covers the cited US metered-dose aerosol, with other device versions excluded.

Does the US label describe this aerosol as a rescue inhaler?

No. It states that the product is not indicated for relief of acute bronchospasm. Follow the clinician's specific action plan.

Why rinse after a budesonide/formoterol inhalation?

The inhaled corticosteroid can cause oral thrush. Rinsing with water and spitting helps reduce that risk.

Related reading

Sources

  1. SYMBICORT: official US prescribing information

Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.

Reviewed by: Mattias Hagman, PhD

About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.

Last reviewed: October 2026